This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Week Ahead In One Click
by Brian Bolan
A look at the important economic data and earnings that are headed your way this week.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
Should You Buy Pfizer (PFE) Ahead of Earnings?
by Zacks Equity Research
Pfizer (PFE) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More
by Arpita Dutt
Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?
by Zacks Equity Research
Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
by Sweta Killa
Results from Johnson and Johnson could be a warning sign for other drug makers, which are scheduled to report this week and the next.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.
Is J&J's Pharma Sales Slowdown a Warning for Other Players?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first-quarter 2017 earnings results on Tuesday.
Lackluster J&J Q1 Pushes Healthcare ETFs Down
by Sweta Killa
Johnson & Johnson continued its long streak of earnings beat but lagged our revenue estimate again on sluggish drug sales.
Why Is Pfizer (PFE) Up 8.7% Since the Last Earnings Report?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down
by Zacks Equity Research
Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.
Did Pharma & Biotech M&As Pick Pace in Q1?
by Arpita Dutt
Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
Roche's Hemophilia A Drug Positive in Second Phase III Study
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.
5 Drug Stocks That Could Be Big Winners this Earnings Season
by Arpita Dutt
Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.
Roche Launches Antibody Test to Diagnose Prostate Cancer
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.
J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?
by Zacks Equity Research
We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.
Aerie Reports Positive Data on Ophthalmic Drug Rhopressa
by Zacks Equity Research
Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.
Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint
by Zacks Equity Research
Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.
Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz
by Swarup Gupta
The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.
Allergan (AGN) Presents Mixed Depression Data on Botox
by Zacks Equity Research
Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).
Paratek (PRTK) Stock Continues to Rise on Positive Results
by Zacks Equity Research
Paratek Pharmaceuticals, Inc.'s (PRTK) shares are up more than 22% since it announced positive results from a phase III study of its lead pipeline candidate
Roche Announces Positive Data on Lung Cancer Drug Alecensa
by Zacks Equity Research
Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.
Mylan's EpiPen Recall Expanded to U.S.
by Madeleine Johnson
On Monday, Mylan NV???s (MYL) manufacturing partner Meridian Medical Technologies announced that it will expand its voluntary recall of the EpiPen to the United States after discussing with the Food and Drug Administration (FDA).